High-dose vitamin D reduces early multiple sclerosis activity

A recent study in France shows that high doses of vitamin D can help reduce disease activity in early multiple sclerosis (MS). Researchers from CHU Nîmes and Université Montpellier tested oral cholecalciferol, with participants taking 100,000 IU every two weeks. The study focused on patients with clinically isolated syndrome (CIS) and early relapsing‑remitting MS. CIS often includes symptoms like inflammation of the optic nerve or spinal cord. Although CIS does not always lead to full MS, it can still pose risks. Vitamin D deficiency is a known risk factor for MS. Previous trials on vitamin D supplementation have shown mixed results. The researchers aimed to see if high doses could work alone, rather than just alongside other treatments. In the D‑Lay MS trial, 316 participants were divided into two groups: one received vitamin D and the other a placebo. Over 24 months, they monitored disease activity, measuring relapses and new MRI lesions. Out of the participants, those taking vitamin D had significantly lower disease activity and a longer time before new symptoms appeared. The findings suggest that high-dose vitamin D may be an effective, low-cost option for treating early MS. The researchers recommend more studies to explore its use alongside other therapies, especially for patients who are severely deficient in vitamin D.